HIVE vs OPY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

HIVE

64.0
AI Score
VS
HIVE Wins

OPY

60.2
AI Score

Investment Advisor Scores

HIVE

64score
Recommendation
HOLD

OPY

60score
Recommendation
STRONG BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE OPY Winner
Forward P/E 62.8931 10.8108 OPY
PEG Ratio 0 12 Tie
Revenue Growth 73.5% -10.4% HIVE
Earnings Growth -99.9% -75.3% OPY
Tradestie Score 64.0/100 60.2/100 HIVE
Profit Margin -98.5% 5.2% OPY
Beta 1.00 1.00 Tie
AI Recommendation HOLD STRONG BUY OPY

Relative Price Performance (Last 90 Days)

HIVE 1M: -26.2% · 3M: -32.2% OPY 1M: -14.5% · 3M: -20.6%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.6%), weak momentum, RSI 36

RSI (14): 35.9 · Price: $1.75

OPY

Markdown
Sell / avoid

Price below a falling SMA50 (slope -6.5%), weak momentum, RSI 39

RSI (14): 38.7 · Price: $91.45

Fundamentals Snapshot

Metric HIVE OPY
Market Cap — —
Forward P/E -3.4 10.8
Trailing P/E — 12.0
Revenue (TTM) — —
Revenue Growth 0.7% -0.1%
Gross Margin 0.4% 0.9%
Operating Margin -0.6% 0.1%
EPS -1.53 7.58
Dividend Yield — 0.01%

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.